8-K: Galectin Therapeutics Unveils Strong NAVIGATE Data

Galectin Therapeutics presented compelling biomarker and clinical data from its NAVIGATE trial, reinforcing belapectin's potential for MASH cirrhosis.

Summary

• Galectin Therapeutics Inc. (GALT) presented an update after its Annual Meeting of Stockholders on December 3, 2025, focusing on the NAVIGATE trial results for belapectin.
• The company's initial top-line data from NAVIGATE, released in December 2024, did not include full biomarker analysis, which was subsequently consolidated and analyzed throughout 2025.
• The 2 mg dose of belapectin showed a lower rate of new varices compared with placebo after 18 months, which was statistically significant in the per protocol or completer population.
• Biomarker analysis consistently supported the primary endpoint data, including improvements in Fibroscan, ELF scores, PRO-C3 (over 50% reduction from baseline at 18 months vs. placebo), and YKL-40 (20% reductions in a higher proportion of treated patients).
• Belapectin was associated with a reduced presence of clinically significant portal hypertension (CSPH) at 18 months, with more treated patients moving from high-risk to no/low-risk categories.
• The trial demonstrated a favorable and consistent safety profile for belapectin, with no drug-related serious adverse events, similar discontinuation rates to placebo, and no drug-induced liver injury.
• NAVIGATE enrolled one of the most advanced compensated MASH cirrhosis populations studied to date, with many patients already meeting CSPH criteria at baseline.
• The company has submitted its FDA package and is anticipating feedback soon, while also exploring strategic opportunities to maximize program value.
• Chairman Richard Uihlein extended the company's cash runway, enabling the achievement of significant milestones in 2025.

Sentiment

Score: 8

Explanation: The detailed analysis of biomarker data strongly supports the clinical findings of belapectin in a high-risk patient population with no approved therapies. The safety profile is excellent, and the company is actively pursuing regulatory and strategic pathways, significantly de-risking the program.

Positives

• Belapectin 2 mg dose achieved a statistically significant lower rate of new varices compared with placebo in the per protocol (completer) population after 18 months.
• Most biomarkers analyzed, including Fibroscan, ELF, Nodic Biosciences specialized biomarkers, and general cytokine biomarkers, supported the primary endpoint data.
• Significantly fewer patients on belapectin 2 mg/kg experienced worsening of liver stiffness (defined as a 30% increase or an absolute 5 kPa rise) compared with placebo.
• PRO-C3, a marker of active fibrogenesis, showed more than a 50% reduction from baseline at 18 months with belapectin 2 mg/kg compared with placebo, indicating a direct antifibrotic effect.
• YKL-40, associated with Galectin-3 activity and liver inflammation, showed 20% reductions in a higher proportion of belapectin-treated patients than placebo.
• Belapectin was associated with a reduced presence of CSPH at 18 months, with more treated patients moving from high-risk to no/low-risk categories.
• Belapectin demonstrated a favorable and consistent safety profile with no drug-related serious adverse events, similar discontinuation rates to placebo, and no drug-induced liver injury.
• The NAVIGATE trial enrolled a highly advanced compensated MASH cirrhosis population, making the positive results particularly impactful.
• The company has submitted its FDA package and is anticipating feedback, indicating progress towards regulatory approval.
• Chairman Richard Uihlein extended the company's cash runway, strengthening its financial position.

Negatives

• The top-line results for the overall population were not statistically significant for the primary endpoint of new varices.
• The decision to unblind the trial at the end of 2024 was not originally planned, leading to a monumental task of consolidating and analyzing a large volume of data in 2025.

Risks

• The primary endpoint was not statistically significant in the overall population, which could pose challenges during regulatory review.
• The company is awaiting FDA feedback, and the outcome of these discussions will be critical for the program's future development and potential approval.
• The need to explore strategic opportunities implies potential for dilution or unfavorable partnership terms if not successfully executed.

Future Outlook

The company anticipates receiving feedback from the FDA soon regarding its submitted package and is actively exploring strategic opportunities to maximize the value of its belapectin program. Management believes the program has the potential to change the treatment landscape for patients with MASH cirrhosis and portal hypertension, a population currently lacking FDA-approved therapies. They look forward to a productive year ahead for the program, shareholders, and patients.

Management Comments

• "I can honestly say that I have never been as excited as I am today, nor have I had the luxury of sharing such an extensive amount of meaningful information." Joel Lewis, President and CEO.
• "frankly, the only appropriate word I can think of is, wow!" Joel Lewis, President and CEO.
• "Without his unwavering support and commitment to our program we would not have achieved the milestones that we have this year." Joel Lewis on Chairman Richard Uihlein.
• "Without Khurram we simply would not be where we today." Joel Lewis on Dr. Khurram Jamil, CMO.
• "We believe that the top-line data alone does not provide a complete picture of the potential benefits of belapectin." Joel Lewis, President and CEO.
• "Our perseverance yielded what we believe to be some extremely compelling results to date, and we are still continuing to analyze data from the trial." Joel Lewis, President and CEO.
• "We believe this program has the potential to change the treatment landscape for a patient population that currently has no FDA approved therapy." Joel Lewis, President and CEO.
• "As we approach 2026, I believe we are stronger than ever, from both a scientific and strategic perspective." Joel Lewis, President and CEO.
• "Throughout 2025, our goal has been to strengthen, validate, and communicate the full body of evidence supporting this clinical finding with belapectin." Dr. Khurram Jamil, CMO.
• "Across all these analyses, the consistency between the clinical outcomes and the biomarker results strengthens our confidence in Belapectins potential for slowing disease progression and improving clinical outcomes in this high-risk population." Dr. Khurram Jamil, CMO.
• "As we finalize the remaining analyses, we look forward to working with the FDA to determine next steps for the program." Dr. Khurram Jamil, CMO.
• "In parallel, we continue active discussions with potential partners who share our commitment to advancing belapectin for patients who currently have no approved treatment options." Dr. Khurram Jamil, CMO.

Industry Context

MASH cirrhosis and portal hypertension represent a large and unfortunately growing patient population with a significant unmet medical need, as there are currently no FDA-approved therapies. Galectin Therapeutics' belapectin, with its demonstrated potential to slow disease progression and improve clinical outcomes, is positioned to address this critical gap. The company's active engagement with Key Opinion Leaders (KOLs) and presentations at major hepatology symposia (EASL, AASLD) indicate its commitment to integrating into and influencing the broader scientific and medical community.

Comparison to Industry Standards

• The NAVIGATE trial enrolled one of the most advanced compensated MASH cirrhosis populations studied to date, with many patients already meeting clinically significant portal hypertension criteria at baseline, which differentiates it from other trials and potentially highlights belapectin's efficacy in a high-risk group.
• The unique nature of the patient population in NAVIGATE has led to groundbreaking discussions with clinicians regarding MASH cirrhosis and portal hypertension.
• Belapectin addresses a significant unmet medical need as there is currently no FDA-approved therapy for patients with MASH cirrhosis and portal hypertension, positioning it as a potential first-in-class treatment.

Related Party Transactions

• Chairman Richard Uihlein extended the company's cash runway, demonstrating his continued commitment and support for the program.

Stakeholder Impact

• Shareholders: Positive impact due to compelling clinical data, extended cash runway, and pursuit of strategic opportunities, potentially increasing program value.
• Patients: Significant potential benefit as belapectin could be the first FDA-approved therapy for MASH cirrhosis and portal hypertension, addressing a major unmet medical need.
• Employees/Consultants: Acknowledged for their tireless efforts in data analysis, indicating a positive internal environment and recognition of their contributions.
• KOLs/Investigators: Re-engaged and encouraged by results, supporting scientific community collaboration and validation of the data.
• FDA: Submitted package, awaiting feedback, indicating regulatory progress and potential for future approval.
• Potential Partners: Active discussions ongoing, suggesting future collaborations that could accelerate development and commercialization.

Next Steps

• Conduct additional KOL events with respect to biomarker data.
• Present at upcoming congresses.
• Publish peer-reviewed articles from NAVIGATE.
• Continue engagement with clinicians regarding MASH cirrhosis and portal hypertension patients.
• Anticipate feedback from the FDA package submission.
• Finalize remaining analyses from the NAVIGATE trial.
• Work with the FDA to determine next steps for the program.
• Continue active discussions with potential partners.

Key Dates

Recommendation

The detailed biomarker data from the NAVIGATE trial provides robust support for belapectin's efficacy in slowing disease progression and improving outcomes in compensated MASH cirrhosis with portal hypertension, a condition with no approved therapies. The statistically significant results in the completer population, coupled with an excellent safety profile and the company's active engagement with the FDA and potential partners, significantly de-risk the program and point towards a strong commercial future. The extension of the cash runway further strengthens the company's position, making it a compelling investment opportunity.

Keywords

Galectin Therapeutics, GALT, MASH cirrhosis, portal hypertension, belapectin, NAVIGATE trial, clinical trial, biomarker, FDA, liver disease, fibrosis, varices, PRO-C3, YKL-40, ELF score, Fibroscan, NASH